Rapid screening of 4000 individuals for germ-line variations in the BRAF gene

Clinical Chemistry

Volumn 52, Issue 9, 2006, Pages 1675-1678

  James, Michael R ^a   Dumeni, Troy ^a   Stark, Mitchell S ^a   Duffy, David L ^a   Montgomery, Grant W ^a   Martin, Nicholas G ^a   Hayward, Nicholas K ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ARTICLE; BRAF GENE; CANCER SUSCEPTIBILITY; CODON; CONTROLLED STUDY; GENE; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA; MELANOMA CELL; POLYMERASE CHAIN REACTION; SCREENING TEST;

CASE-CONTROL STUDIES; CELL LINE, TUMOR; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; GERM-LINE MUTATION; HUMANS; MELANOMA; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 33748325725     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.070169     Document Type: Article

References (33)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
2. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
3. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003;63:3883-5.
4. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003;63:3955-7.
5. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003;9:3362-8.
6. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Bobbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
7. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
8. Laud K, Kannengiesser C, Avril MF, Chompret A, Stoppa-Lyonnet D, Desjardin L, et al. BRAF as a melanoma susceptibility candidate gene? Cancer Res 2003;63:3061-5.
9. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004;23:4060-7.
10. Yazdi AS, Palmedo G, Flaig MJ, Kutzner H, Sander CA. SP-11 Different frequencies of a BRAF point mutation in melanocytic skin lesions. Pigment Cell Res 2003;16:580.
11. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
12. Morrison DK. Enzymes play molecular tag. Nature 2004;428:813-4.
13. Meyer P, Sergi C, Garbe C. Polymorphisms of the BRAF gene predispose males to malignant melanoma. J Carcinogen 2003;2:7.
14. James MR, Roth RB, Shi MM, Kammerer S, Nelson MR, Stark MS, et al. BRAF polymorphisms and risk of melanocytic neoplasia. J Invest Dermatol 2005;125:1252-8.
15. Pollock PM, Trent JM. The genetics of cutaneous melanoma. Clin Lab Med 2000;20:667-90.
16. Aitken JF, Welch J, Duffy DL, Milligan A, Green A, Martin N, et al. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 1999;91:446-52.
17. Casula M, Colombino M, Satta MP, Cossu A, Ascierto PA, Bianchi-Scarra G, et al. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian melanoma intergroup study. J Clin Oncol 2004;22:286-92.
18. Aitken JF, Duffy DL, Green A, Youl P, MacLennan R, Martin NG. Heterogeneity of melanoma risk in families of melanoma patients. Am J Epidemiol 1994;140:961-3.
19. Aitken JF, Green A, MacLennan R, Youl P, Martin NG The Queensland Familial Melanoma Project: study design and characteristics of participants. Melanoma Res 1996;6:155-65.
20. Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation pheno-type? Am J Hum Genet 2000;66:176-86.
21. Zhu G, Duffy DL, Eldridge A, Grace M, Mayne C, O'Gorman L, et al. A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet 1999;65:483-92.
22. Zhu G, Evans DM, Duffy DL, Montgomery GW, Medland SE, Gillespie NA, et al. A genome scan for eye color in 502 twin families: most variation is due to a QTL on chromosome 15q. Twin Res 2004;7:197-210.
23. Bansal A, van den Boom D, Kammerer S, Honisch C, Adam G, Cantor CR, et al. Association testing by DNA pooling: an effective initial screen. Proc Natl Acad Sci U S A 2002;99:16971-874.
24. James MR, Haywayd NK, Dumenil T, Montgomery GW, Martin NG, Duffy DL EGF polymorphism and risk of melanocytic neoplasia. J Invest Dermatol 2004;123:760-2.
25. Sun X, Ding H, Hung K, Quo B A new MALDI-TOF based mini-sequencing assay for genotyping of SNPs. Nucleic Acids Res 2000;28:e68.
26. Tanami H, Hirasawa A, Yuki Y, Sonoda I, Inoue J, Yasui K, et al. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 2004;23:8796-804.
27. Casula M, Colombino M, Satta MP, Cossu A, Ascierto PA, Bianchi-Scarra G, et al. Errata to :BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian melanoma intergroup study. J Clin Oncol 2005;23:936.
28. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-7.
29. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YW, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7.
30. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE Tumorigenesis: RAF/RAS oncogenes and mis-match-repair status. Nature 2002;418:934.
31. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002;62:6451-5.
32. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002;62:7001-3.
33. Rodriguez-Viciana P, Tetsu O, Tidyman We, Estep AL, Conger BA, Santa Cruz M, et al. Germline mutations in genes within the MAPK pathway cause Cardio-facio-cutaneous syndrome. Science 2006;311:1287-90.